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Abstract
Background: While many common chemotherapeutic drugs and other inducers of DNA-damage
result in both NF-κB nuclear translocation and DNA-binding, we have previously observed that,
depending on the precise stimulus, there is great diversity of the function of NF-κB. In particular,
we found that treatment of U-2 OS osteosarcoma cells with the anthracycine daunorubicin or with
ultraviolet (UV-C) light resulted in a form of NF-κB that repressed rather than induced NF-κB
reporter plasmids and the expression of specific anti-apoptotic genes. Anthracyclines such as
daunorubicin can induce DNA-damage though inhibiting topoisomerase II, intercalating with DNA
and undergoing redox cycling to produce oxygen free radicals. In this study we have investigated
other anthracyclines, doxorubicin and aclarubicin, as well as the anthracenedione mitoxantrone
together with the topoisomerase II inhibitor ICRF-193, which all possess differing characteristics,
to determine which of these features is specifically required to induce both NF-κB DNA-binding
and transcriptional repression in U-2 OS cells.
Results: The use of mitoxantrone, which does not undergo redox cycling, and the reducing agent
epigallocatechingallate (EGCG) demonstrated that oxygen free radical production is not required
for induction of NF-κB DNA-binding and transcriptional repression by these agents and UV-C. In
addition, the use of aclarubicin, which does not directly inhibit topoisomerase II and ICRF-193,
which inhibits topoisomerase II but does not intercalate into DNA, demonstrated that
topoisomerase II inhibition is not sufficient to induce the repressor form of NF-κB.
Conclusion: Induction of NF-κB DNA-binding and transcriptional repression by topoisomerase II
inhibitors was found to correlate with an ability to intercalate into DNA. Although data from our
and other laboratories indicates that topoisomerase II inhibition and oxygen free radicals do
regulate NF-κB, they are not required for the particular ability of NF-κB to repress rather than
activate transcription. Together with our previous data, these results demonstrate that the nature
of the NF-κB response is context dependent. In a clinical setting such effects could profoundly
influence the response to chemotherapy and suggest that new methods of analyzing NF-κB function
could have both diagnostic and prognostic value.
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Background
In mammalian cells, the NF-κB family of transcription fac-
tors is composed of homodimers and heterodimers
derived from five distinct subunits, RelA(p65), c-Rel,
RelB, p50 (NF-κB1) and p52 (NF-κB2) [1]. Of these, p50
and p52 arise from proteolytic degradation of larger pre-
cursor proteins, p105 and p100 respectively. In unstimu-
lated cells, the majority of NF-κB complexes are kept
predominantly cytoplasmic and in an inactive form by
binding to a family of inhibitory proteins, the IκBs. Acti-
vation of NF-κB typically involves the phosphorylation of
IκBs by IκB kinase (IKK) β (IKK2), a component of the
IKK complex, which includes one other catalytic subunit,
IKK α (IKK1), and a regulatory subunit IKK γ (NEMO) [1].
Many stimuli induce IKK activity through a variety of
mechanisms [1]. Phosphorylation of IκB results in its
ubiquitination and degradation by the proteasome. This
frees NF-κB complexes to translocate to the nucleus. Aber-
rantly active NF-κB is associated with many human dis-
eases, particularly those of an inflammatory origin [2].
Over the last few years, however, it has also become
apparent that NF-κB plays critical roles in tumorigenesis
and the response to cancer therapy [3,4].
Nuclear translocation and subsequent DNA-binding rep-
resent critical steps in the NF-κB pathway. However, the
functional consequences of NF-κB activation, in terms of
gene transcription, can differ dramatically depending on
the nature of the inducer and the cellular context [4-6].
These differences derive from a wide variety of regulatory
mechanisms that control the promoter targeting and
transactivation functions of the NF-κB subunits [5]. Previ-
ously, we have demonstrated that the response of NF-κB
to cytotoxic agents can exhibit great diversity [7,8]. While
inflammatory stimuli such as tumor necrosis factor α
(TNF) result in RelA-dependent induction of anti-apop-
totic genes such as Bcl-xL and XIAP, other stimuli, such as
treatment with ultraviolet light (UV-C) and the chemo-
therapeutic drug daunorubicin (also known as daunomy-
cin) resulted in RelA-dependent transcriptional repression
of these same genes [7]. These differences do not simply
derive from the effects of DNA-damage. We also observed
that the chemotherapeutic drug etoposide induced an
activator form of NF-κB that behaved more similarly to
TNF induced NF-κB [8]. Furthermore, treatment with the
cancer drug cisplatin, which induces DNA-damage
through DNA cross-linking, revealed that in the same U-2
OS osteosarcoma cell line used for the analysis of the
other compounds, no induction of NF-κB DNA-binding
occurred. Cisplatin, however, modulated RelA transcrip-
tional activity, resulting in repression of Bcl-xL but not X-
IAP expression [8]. Further analysis demonstrated that
regulation of RelA transactivation by cisplatin shares
many features with effects we had previously observed
upon induction of the ARF tumor suppressor [8].
Together, these results reveal that the response of NF-κB to
different cytotoxic agents and chemotherapeutic drugs,
within the same tumor cell line, can demonstrate dra-
matic functional differences. Such differences could have
consequences for the effectiveness of cancer treatment in
patients and imply that improved diagnosis and choice of
therapy might result from a more in depth knowledge of
the mechanisms underlying these effects.
Although treatment with these chemotherapeutic drugs
results in DNA-damage, this can occur through different
mechanisms [9-11]. In addition, they often have other
properties with the potential to result in specific biologi-
cal effects (Table 1). For example, the anthracycline dau-
norubicin, which is primarily used in the treatment of
acute myeloid leukemia and its congener doxorubicin
(also known as adriamycin), which is used to treat a vari-
ety of solid tumours, osteosarcomas, soft-tissue sarcomas
and non-Hodgkins lymphoma [12,13], can induce DNA-
damage through inhibition of topoisomerase II [12].
These drugs inhibit the action of topoisomerase II after
induction of double strand DNA breaks resulting in cova-
lent attachment between active site residues of topoi-
somerase II and the 5' of the DNA ends [10,12,14]. Both
daunorubicin and doxorubicin also intercalate into DNA
Table 1: Summary of the different characteristics of the compounds used in this study and their effect on NF-κB. Our previous work on 
the effects of daunorubicin and etoposide on NF-κB are described in references [7, 8]. * Inhibition of topoisomerase II by aclarubicin is 
indirect and does not result from covalent attachment of topoisomerase II to DNA.
Topo II inhibition Topo II inhibition 
induced DNA-
damage
DNA intercalation Generation of 
oxygen free 
radicals
Induction of NF-
κB DNA-binding
Repression or 
activation of 
transcription
Daunorubicin Yes Yes Yes Yes Yes Repression
Doxorubicin Yes Yes Yes Yes Yes Repression
Mitoxantrone Yes Yes Yes No Yes Repression
Aclarubicin Yes* No Yes Yes Yes Repression
ICRF 193 Yes No No No No No effect
Etoposide Yes Yes No No Yes ActivationBMC Cancer 2006, 6:101 http://www.biomedcentral.com/1471-2407/6/101
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and alter helical torsion, which also results in DNA-dam-
age [10,12,14]. Thus, these compounds can essentially
induce DNA-damage through 2 distinct mechanisms.
Daunorubicin and doxorubicin also undergo redox
cycling and generate oxygen free radicals, which can have
a variety of effects, including damage to cell membranes
but also provides a third mechanism of inducing DNA-
damage [12]. Indeed, free radical generation by anthracy-
clines is thought to be responsible for the cardiotoxicity
that limits their therapeutic use [15,16]. NADPH-flavin
reductase, cytochrome p450 reductase and mitochondrial
NADH reductase can all reduce anthracyclines to a semiq-
uinone radical [17]. This semiquinone radical can donate
its free electron to molecular oxygen to generate the super-
oxide radical (O•
2) [17]. Like hydrogen peroxide (H2O2),
O•
2 can generate hydroxyl radicals (•OH) upon interac-
tion with metal ions [17]. This results in lipid peroxida-
tion of plasma membranes, leading to a loss of
mitochondrial inner membrane potential and conse-
quent cytochrome c release and apoptosis. Reactive oxy-
gen species can also directly damage DNA through
generation of strand breaks and oxidized nucleic bases
such as guanine to 8-hydroxyguanine, giving rise to G-T
transversions [17]. UV-C also induces free radical forma-
tion by homolytic fission of hydrogen peroxide, inducing
single strand DNA breaks [17]. Oxygen free radicals have
been shown to induce NF-κB DNA-binding under some
circumstances and could potentially represent a key com-
ponent of the ability of cytotoxic agents to differentially
regulate NF-κB function [18-20].
A feature of anthracyclines and other topoisomerase II
inhibitors, is that, at least in part, these different character-
istics derive from distinct molecular features and can be
functionally separated. For example, the anthracyclines
daunorubicin, doxorubicin and aclarubicin all share pla-
nar ring structures that intercalate into DNA [9,10,12].
The anthracenedione mitoxantrone also possesses a pla-
nar structure and intercalates with DNA while inhibiting
topoisomerase II but unlike the anthracyclines does not
undergo redox cycling to generate semiquinone radicals
that result in free radical generation [10,16,21]. Mitox-
antrone is therefore useful clinically since it results in
reduced levels of cardiotoxicity [16]. Structural differences
in aclarubicin (aclacinomycin A), which is used in the
treatment of acute myelocytic leukemia, mean that it can
intercalate into DNA, resutling in DNA-damage and pre-
vention of topoisomerase II DNA-binding, but it does not
stabilize a Topoisomerase II-DNA complex like the other
anthracyclines [9]. Therefore, any DNA-damage induced
does not result from double stranded DNA-breaks
induced by inactivation of topoisomerase II.
Etoposide, an epipodophyllotoxin, is used to treat small
cell lung cancers, leukemias, lymphomas and germ-line
malignancies [10]. As described above, etoposide inhibits
topoisomerase II activity resulting in DNA strand breaks
but has the opposite effect to daunorubicin/doxorubicin
on NF-κB, strongly stimulating NF-κB transcriptional
activity [7,8]. Etoposide does not intercalate into DNA nor
does it generate free radicals [10,14]. These observations
all suggested that multiple factors determine NF-κB func-
tion in response to cytotoxic agents such as chemothera-
peutic drugs and that induction of DNA-binding is a
separable regulatory event from modulation of transacti-
vation. Moreover, they indicate that it is not topoisomer-
ase II inhibition and DNA-strand breaks per se that result
in forms of NF-κB that repress transcription. Therefore, to
help determine which characteristics of these compounds
are required for different functions of NF-κB, we have
investigated the response of NF-κB, both in terms of DNA-
binding and transcriptional activity, to multiple topoi-
somerase II inhibitors with defined characteristics. In
addition we have investigated the ability of an additional
topoisomerase II inhibitor, the bis-dioxopiperazine com-
pound ICRF-193, which is a catalytic inhibitor of topoi-
somerase II that stabilizes an inactive, closed clamp
conformation of the enzyme that deprives the cell of top-
isomerase II catalytic activity, resulting in apoptosis with-
out directly generating DNA breaks [22,23]. Furthermore,
we have also analyzed the contribution of oxygen free rad-
ical generation to regulation of NF-κB function. Our
results suggest that DNA-damage is required to induce NF-
κB activity but whether this is achieved through DNA-
intercalation or topoisomerase II inhibition will deter-
mine the function of the induced NF-κB complexes.
Results
Induction of NF-κB DNA-binding
All experiments in this report were performed in U-2 OS
cells, a human osteosarcoma cell line. This provides con-
tinuity both within this investigation and with our previ-
ous published data [7,8]. It is likely, however, that results
will vary in other cell lines and therefore while this data
reveals the variability possible within a single tumour cell
type, extrapolation to other cells should be performed
with caution. Indeed, where possible, the effects of these
drugs in different systems should be determined empiri-
cally.
We first investigated the ability of different topoisomerase
II inhibitors to induce NF-κB DNA-binding. Previously we
have shown that daunorubicin and UV-C induce NF-κB
DNA-binding with delayed kinetics relative to an inducer
such as TNF [7]. Together with other data in the literature
suggesting differences in their mechanism of IKK activa-
tion, this has lead us to designate daunorubicin and UV-C
as atypical inducers of NF-κB while TNF is a prototypicalBMC Cancer 2006, 6:101 http://www.biomedcentral.com/1471-2407/6/101
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example of a typical inducer [7,24]. In addition, we have
also shown previously that etoposide is also a strong
inducer of NF-κB DNA-binding in U-2 OS cells [8]. Con-
sistent with this previous data, doxorubicin, which is
structurally very similar to daunorubicin [12], also
induced NF-κB DNA-binding with delayed kinetics (Fig.
1). Interestingly, mitoxantrone, which does not undergo
redox cycling and therefore does not produce free radicals
[16], was also a strong inducer of NF-κB DNA-binding
(Fig. 1). Indeed, induction of NF-κB DNA-binding
occurred more rapidly than with doxorubicin, suggesting
that if anything, under these conditions, oxygen free radi-
cals delay NF-κB activation, in contrast to their previously
ascribed role as cell type specific inducers of NF-κB [18-
20]. Significantly, aclarubicin, which intercalates with
DNA [9], also induced NF-κB DNA-binding while ICRF-
193, which inhibits topoisomerase II but does not directly
induce DNA-damage [22,23], did not (Fig. 1). These
observations are summarized in Table 1.
Production of oxygen free radicals is not required for 
induction of NF-κB DNA-binding by anthracyclines
To confirm the apparent lack of a requirement for oxygen
free radical generation for induction of NF-κB DNA bind-
ing, implied by the effect of mitoxantrone, we investigated
the effect of reducing agents. Although reactive oxygen
species have been shown to activate NF-κB in a cell con-
text dependent manner [19,20], it has been recently
shown that many of the compounds used in studies to
neutralize free radicals in themselves could inhibit NF-κB
Induction NF-κB DNA binding by topoisomerase II inhibitors  and DNA-intercalators Figure 1
Induction NF-κB DNA binding by topoisomerase II inhibitors 
and DNA-intercalators. U-2 OS cells were stimulated with 1 
µM aclarubicin, 1 µM daunorubicin, 1 µM doxorubicin, 2.5 
µM mitoxantrone and 4 µM ICRF-193, for the times indi-
cated. Nuclear protein extracts were prepared and 5 µg was 
subjected to EMSA analysis using a 32P labelled HIV-1 κB oli-
gonucleotide.
Oxygen free radical generation is not required for induction  of NF-κB DNA-binding Figure 2
Oxygen free radical generation is not required for induction 
of NF-κB DNA-binding. U-2 OS cells were stimulated with 
(A) 1 µM daunorubicin, (B) 2.5 µM mitoxantrone (C) 40 J/m2 
UV-C, or for the indicated times with, or without 1 hour 
pre-incubation with 20 µM EGCG or 10 mM NAC as indi-
cated.BMC Cancer 2006, 6:101 http://www.biomedcentral.com/1471-2407/6/101
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activity. For example, N-acetyl-L-cysteine (NAC) and pyr-
rolidine dithiocarbamate (PDTC), anti-oxidants com-
monly used in studies of NF-κB activation, prevented TNF
induced NF-κB DNA binding independent of their anti-
oxidant activity [25]. NAC was shown to lower the affinity
of TNF for its receptor, whilst PDTC inhibited the IκB-
ubiquitin ligase activity. In contrast, alternative antioxi-
dants such as epigallocatechingallate (EGCG), the main
component of green tea, and trolox, a soluble vitamin E
analogue (both strong phenolic radical scavengers) did
not affect TNF induced NF-κB activation [25].
We therefore compared the ability of both EGCG and
NAC to inhibit daunorubicin induced NF-κB DNA-bind-
ing. Consistent with our observation that mitoxantrone is
a strong inducer, EGCG had no significant effect on NF-κB
DNA-binding (Fig. 2A). In contrast, NAC inhibited both
daunorubicin and, interestingly, mitoxantrone induced
NF-κB DNA-binding (Fig. 2A & B). This latter effect con-
firms that NAC is a free-radical independent inhibitor of
NF-κB. We also investigated the effect of these com-
pounds on UV-C induced NF-κB DNA-binding, since free-
radical generation is also a component of the effect of this
stimulus. Similarly, EGCG did not inhibit UV-C induced
NF-κB DNA-binding while NAC did (Fig. 2C). In this
experiment EGCG treatment appeared to result in earlier
induction of NF-κB by UV-C, more akin to that seen with
mitoxantrone, suggesting that oxygen free radicals might
affect the kinetics of NF-κB activation. Consistent with
this, etoposide, which also does not induce free radicals,
similarly induces NF-κB more rapidly [8].
These results, together with our previous data, suggest that
DNA-damage is required for induction of NF-κB DNA-
binding and that this can occur either through DNA-inter-
calation or topoisomerase II inhibition. But neither topoi-
somerase II inhibition per se, or production of oxygen free
radicals are required for this effect. Of course, we cannot
rule out some other, unknown, DNA-damage independ-
ent, effect of these drugs that also influences these proc-
esses.
Topoisomerase II inhibition does not induce NF-κB 
dependent transcriptional repression
We next investigated effects on transcriptional activity.
Significantly, and similar to our previously observed
effects with daunorubicin and UV-C [7], both mitox-
antrone and aclarubicin treatment repressed the activity of
a 3 × κB reporter plasmid despite being inducers of NF-κB
DNA-binding, (Fig. 3). We had previously found that cis-
platin treatment of U-2 OS cells, while not inducing NF-
κB DNA-binding does modulate the activity of the basal
level of active NF-κB found in these cells [8]. Therefore,
although ICRF-193 did not induce DNA-binding by NF-
κB, we also determined whether it would have any effect
on transcription. In this case however, ICRF-193 did not
affect the activity of either the 3 × κB reporter plasmid or
Bcl-xL and XIAP (Fig. 3 and see also 4C). Therefore, inhi-
bition of topoisomerase II alone does not appear to affect
NF-κB function in U-2 OS cells.
Oxygen free radicals do not induce NF-κB dependent 
transcriptional repression
Although oxygen free radicals are not required for induc-
tion of NF-κB DNA-binding by topoisomerase II inhibi-
tors, it remained possible that they might affect
transcriptional activity. We therefore investigated the
effect of EGCG on daunorubicin induced NF-κB depend-
ent repression of transcription. No effect was seen, how-
ever, with both the 3 × κB reporter plasmid or upon
endogenous Bcl-xL expression (Fig. 4A & B). Identical
results were also seen with UV-C (Fig. 4A & B). In addi-
tion, consistent with the result seen in Fig. 3, mitox-
antrone still repressed the expression of endogenous Bcl-
xL and XIAP (Fig. 4C). Repression of endogenous Bcl-xL
and XIAP expression by daunorubicin, doxorubicin and
mitoxantrone was confirmed by quantitative RT-PCR
Mitoxantrone and aclarubicin but not ICRF-193, repress NF- κB reporter plasmid activity Figure 3
Mitoxantrone and aclarubicin but not ICRF-193, repress NF-
κB reporter plasmid activity. U-2 OS cells were transfected 
with 2 µg of 3 × κB ConA luciferase reporter plasmid and 36 
hours later stimulated with 4 µM ICRF-193, 1 µM aclarubicin 
or 2.5 µM mitoxantrone for 8 hours. Results are normalised 
such that no change in luciferase activity has a value of 0.BMC Cancer 2006, 6:101 http://www.biomedcentral.com/1471-2407/6/101
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Oxygen free radical generation is not required for NF-κB dependent repression of transcription Figure 4
Oxygen free radical generation is not required for NF-κB dependent repression of transcription. (A) U-2 OS cells were trans-
fected with 2 µg of 3 × κB ConA luc and 36 hours after transfection cells were unstimulated (control) or stimulated for 8 
hours with 1 µM daunorubicin or 40 J/m2 UV-C, with, or without, 1 hour pre-stimulation with 20 µM EGCG, as indicated. (B) 
U-2 OS cells were unstimulated (control) or stimulated for 6 hours with 1 µM daunorubicin or 40 J/m2 UV-C, with, or without, 
1 hour pre-stimulation with 20 µM EGCG, as indicated. Total RNA was prepared and semi-quantitative PCR analysis with 
primers specific to human Bcl-xL and GAPDH. (C) Mitoxantrone inhibits Bcl-xL and XIAP mRNA levels. U-2 OS cells were 
stimulated for 6 hours with 4 µM ICRF-193, 2.5 µM mitoxantrone and 1 µM doxorubicin. Total RNA was prepared and semi-
quantitative PCR analysis performed using primers to human Bcl-xL, XIAP and GAPDH control. (D) Quantitative RT-PCR anal-
ysis. The effects of danuorubicin, doxorubicin and mitoxantrone on Bcl-xL and XIAP mRNA levels was confirmed by quantita-
tive real-time PCR analysis.BMC Cancer 2006, 6:101 http://www.biomedcentral.com/1471-2407/6/101
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analysis (Fig. 4D). Therefore, taken together, oxygen free
radicals do not appear to affect NF-κB transcriptional
activity induced by topoisomerase II inhibitors and UV-C
in U-2 OS cells.
Discussion
The results in this report, together with our previous pub-
lished observations [7,8] highlight the diversity of the NF-
κB response to different chemotherapeutic drugs and
cytotoxic stimuli in U-2 OS cells. Some stimuli, such as
TNF and etoposide, induce both NF-κB DNA-binding and
target gene expression. Other stimuli, however, such as
the topoisomerase II inhibitors daunorubicin, doxoru-
bicin, mitoxantrone and aclarubicin, together with ultra-
violet light, induce NF-κB DNA-binding but result in the
repression of NF-κB dependent gene expression. Other
pathways, induced by cisplatin and the ARF tumor sup-
pressor, do not appear to affect NF-κB nuclear localization
but rather modulate the activity of NF-κB, resulting in a
more selective repression of NF-κB target genes [8]. These
effects imply multiple NF-κB regulatory pathways and
that NF-κB subunit transactivation can be a separate regu-
latory event to nuclear translocation. Here, we have
focused on the different known characteristics of anthra-
cyclines and other topoisomerase II inhibitors to begin to
determine which of these features are critical for specific
effects on NF-κB function.
It is apparent that DNA-damage per se does not induce a
defined effect on NF-κB function. As these compounds
can induce DNA-lesions in different ways and also have
other cellular effects, we were interested in which of these
were required for NF-κB regulation. A straightforward
interpretation of our data would indicate that those com-
pounds capable of intercalating with DNA all induce NF-
κB DNA-binding together with repression of NF-κB
reporter plasmids and the target genes Bcl-xL and XIAP
(Table 1). By contrast, when topoisomerase II inhibition
results in DNA damage, as is seen with etoposide, induc-
tion NF-κB DNA-binding is seen but with activation
rather than repression of NF-κB transactivation [8].
Although some compounds are capable of both interca-
lating with DNA and inhibiting topoisomerase II (Table
1) we have previously observed that transcriptional
repressive effects on NF-κB are dominant over transcrip-
tional activatory effects [7,8], possibly accounting for
why, with these compounds we see repression. Further-
more, DNA-damage appears to be a requirement for
effects on NF-κB since ICRF-193 treatment results in
topoisomerase II inhibition alone and here we see no
effect (Table 1).
This might be an overly simplistic interpretation, how-
ever, since Bilyeu and co-workers recently showed that
DNA damage was not necessary for anthracycline induced
NF-κB activation [26]. To do this they utilized cytoplasmi-
cally localized anthracycline derivatives, which surpris-
ingly still induce NF-κB DNA-binding. Immobilized
(extracellular) or free (intracellular) anthracyclines, have
also been reported to activate NF-κB DNA binding, yet
immobilized daunorubicin and doxorubicin induced
necrosis rather than apoptosis, the effect typically seen
with these compounds [27]. These studies raise the ques-
tion of whether DNA damage is in fact required for induc-
tion of NF-κB activity by topoisomerase II inhibitors.
Furthermore, some reports do suggest that ICRF-193 treat-
ment will result in DNA-damage as a secondary conse-
quence of topoisomerase II inhibition [28], underlining
that the effects of these compounds are often somewhat
overlapping and caution should be taken interpreting
there effects.
Another feature of some anthracyclines is their ability to
generate oxygen free radicals resulting from redox cycling.
We demonstrated, however, through the use of mitox-
antrone and the free radical neutralizer EGCG that this
effect is not required for induction of NF-κB DNA-binding
and repression of NF-κB target genes (Table 1). DNA-
binding assays with both mitoxantrone and EGCG treated
cells did suggest that oxygen free radicals might affect the
timing of NF-κB induction, with free radical production
potentially inducing a delay in the kinetics of NF-κB acti-
vation. The mechanism for this is unknown and will
require further research but could involve direct effects on
the dimerisation and DNA-binding of NF-κB subunits
themselves, which have been shown to possess reactive
cysteine residues sensitive to cellular redox status [29].
Interestingly, NAC, which has been shown to inhibit NF-
κB through pathways independent of its ability to func-
tion as a reducing agent [25], also inhibited NF-κB activity
induced by daunorubicin and UV-C while EGCG did not.
This suggests that the non-specific inhibitory effects of this
compound are quite broad and previous results obtained
with it should be treated with caution.
One possibility is that all the effects of these compounds,
DNA intercalation, topoisomerase II inhibition and free
radical generation, affect NF-κB and are capable of induc-
ing its nuclear translocation and DNA-binding separately.
This might also account for the effects seen by Bilyeu et al.,
which could derive from cytoplasmic effects or oxygen
free radical production. However, it is likely that the func-
tional consequences of these different characteristics are
different. In this regard, it is DNA-intercalation and the
subsequent effects it induces that result in repression of
NF-κB dependent transcription. This implies that DNA-
damage induced by this pathway has effects distinct to
those seen by other forms of DNA-damage. The precise
nature of these will be the subject of future investigations.
Our previous results also suggest that the pathways thatBMC Cancer 2006, 6:101 http://www.biomedcentral.com/1471-2407/6/101
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result in NF-κB dependent repression of transcription
induced by UV-C and cisplatin/ARF are different from
each other and also those induced by topoisomerase II
inhibitors and DNA-intercalators. Therefore, there is
likely to be much complexity in the pathways that regulate
the function of NF-κB subunits after they translocate to
the cell nucleus. However, since these pathways are being
induced by drugs commonly used in cancer therapy,
understanding them could be of great diagnostic and
prognostic value. As NF-κB can exhibit such a diverse set
of responses to such treatments, care should be taken
when predicting its role in tumorigenesis and the
response to chemotherapeutic drug therapy.
Conclusion
Induction of NF-κB DNA-binding and transcriptional
repression by clinically utilized topoisomerase II inhibi-
tors and DNA-intercalators correlates with their ability to
intercalate into DNA and not with topoisomerase II inhi-
bition or oxygen free radical production. These latter
effects have been shown to affect NF-κB function in other
circumstances but our data implies that the particular sig-
naling events initiated by the DNA-damage resulting from
helical torsion generated by DNA-intercalation, specifi-
cally target the transactivation functions of NF-κB. Our
previous data indicates that this will involve the differen-
tial phosphorylation of the RelA(p65) NF-κB subunit
[24].
These different characteristics and effects on NF-κB could
have important clinical effects and also impact future drug
design. Drugs that result in forms of NF-κB that repress
anti-apoptotic gene expression might be more clinically
effective. The challenge will be to be able to predict which
effects will be seen in patients since these effects are likely
to be both cell and tumour type specific. Nonetheless,
there is the potential for the development of new diagnos-
tic and prognostic tools. It is interesting to note that dox-
orubicin and cisplatin, both of which, in U-2 OS
osteosarcoma cells, result in NF-κB dependent repression
of anti-apoptotic target genes through different mecha-
nisms [7,8] are used in combination for the treatment of
osteosarcoma in the clinic [13]. Whether these effects con-
tribute to their effectiveness in the clinic and whether
patients who do not respond to therapy have lost these
NF-κB regulatory pathways, will require further research.
It is also possible, that further knowledge of these path-
ways can help in future drug design and discovery.
Methods
Cells
U-2 OS osteosarcoma cells were obtained from the Euro-
pean Collection of Cell Cultures and were not grown
beyond passage 35. Cell were grown at 37°C with 5%
CO2 in Dulbecco's Modified Eagles Medium (DMEM)
containing 10% Fetal Bovine serum and antibiotics.
Where indicated, endogenous NF-κB activity was induced
by 1 µM aclarubicin (Sigma), 1 µM daunorubicin (Affin-
iti), 1 µM doxorubicin (Affiniti), 2.5 µM mitoxantrone
(Sigma) and 4 µM ICRF-193 (Affiniti) or 40 J/m2 UV-C
(254 nm) using a Stratalinker (Stratagene).
Quantitative Real Time (RT) PCR
RNA was extracted from untreated cells or cells treated
with daunorubicin, doxorubicin or mitoxantrone using
the Nucleospin II kit (Machery-Nagel) according to man-
ufacturer's instructions. 10 ng RNA was used per reaction.
Quantative RT-PCR was performed using the SuperScript™
III Platinum® SYBR® Green One-Step qRT-PCR Kit (Invitro-
gen) together with gene specific QuantiTect® Primers (Qia-
gen), as per manufacturers instructions. Data was
generated on a Rotor-Gene 3000 (Corbett Research) using
the following experimental settings: Hold 50°C for 3 min;
Hold 95°C 5 min; Cycling (95°C for 15 sec; 55°C for 30
sec; 72°C for 15 sec with fluorescence measurement) ×
45; Melting Curve 50–99°C with a heating rate of 1°C
every 5 sec. All values were calculated relative to untreated
levels and normalised to GAPDH levels using the Pfaffl
method [30]. Each RNA sample was assayed in triplicate
and the results shown are representative of three separate
experiments.
Other experimental procedures
All reporter plasmid luciferase assays, semi-quantitative
PCR and electrophoretic mobility shift assays (EMSA)
were performed as described previously [7,31,32]. All
plasmids and PCR primers siRNAs have been described
and characterized before [7,31,32]. Luciferase assays were
performed according to the manufacturer's instructions
(Promega) and results were normalized for protein con-
centration with all experiments performed a minimum of
three times before calculating means and standard devia-
tion as shown in the figures.
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